Last updated: May 21, 2026
Cefoetan (cefotetan disodium) is an older, injection-only second-generation cephalosporin with a limited modern trial pipeline. For an evidence-based clinical trials update and market projection, there must be a definable, current product used in active Phase 2/3 studies or a clearly documented commercial launch with current sales reporting. With the information provided here, a complete, accurate trial and market projection cannot be produced.
What clinical trials are currently updating for CEFOTETAN?
Featured snippet answer: No current, ongoing Phase 2/3 clinical trial dataset can be validated from the information provided, so a clinical trials update for CEFOTETAN cannot be completed.
Which indication areas have active cefotetan studies?
- Surgical prophylaxis (historically)
- Intra-abdominal infection (historically)
- Gynecologic infections (historically)
- Respiratory and urinary infections (historically)
What are the latest Phase 1/2/3 status changes?
- Not available from the provided inputs.
What do trial registries show for recruitment, results, and endpoints?
- Not available from the provided inputs.
What is the current FDA and regulatory status of CEFOTETAN?
Featured snippet answer: A precise FDA status summary (Orange Book, labeling, reference product, and any recent regulatory actions) cannot be produced from the information provided.
What is the Orange Book status of cefotetan?
- Not available from the provided inputs.
Is cefotetan under active REMS or safety labeling updates?
- Not available from the provided inputs.
What FDA labeling claims exist by dosage form?
- Not available from the provided inputs.
What patents protect CEFOTETAN and how strong is the patent estate?
Featured snippet answer: Patent protection scope and expiration dates cannot be compiled accurately from the information provided.
Which patent types typically cover cefotetan?
- Composition of matter (drug substance and salts)
- Formulation (dosage form and excipients)
- Manufacturing process
- Method of use (indication and dosing regimens)
How many patents cover cefotetan across key jurisdictions?
- Not available from the provided inputs.
When does CEFOTETAN lose exclusivity?
- Not available from the provided inputs.
When does CEFOTETAN lose exclusivity and what generic entry risks exist?
Featured snippet answer: Generic launch scenarios tied to Orange Book expiration and Paragraph IV pathways cannot be evaluated from the information provided.
Are there Paragraph IV challenges filed for cefotetan?
- Not available from the provided inputs.
What is the biosimilar risk profile?
- Not applicable to cefotetan as a small-molecule antibiotic, unless a different biologic product is being referenced.
What are the most likely generic market entry timelines?
- Not available from the provided inputs.
How large is the market for CEFOTETAN and what does the competitive landscape look like?
Featured snippet answer: A quantified market size and forecast cannot be produced from the information provided.
Who competes with cefotetan in IV cephalosporins?
- Other second-generation cephalosporins (varies by geography and formulary)
- Broader-spectrum beta-lactams used in surgical prophylaxis and intra-abdominal infection
- Carbapenems and beta-lactam/beta-lactamase inhibitor combinations in higher-acuity settings
What share does cefotetan capture in surgical prophylaxis?
- Not available from the provided inputs.
What procurement and hospital formulary dynamics matter most?
- Not available from the provided inputs.
What market projections should investors and licensors use for CEFOTETAN?
Featured snippet answer: No defendable forecast can be made without verified baseline sales and current demand drivers. Those inputs are not present here.
What revenue model assumptions would drive a cefotetan forecast?
- Hospital usage volume by indication
- Price erosion from generics (if applicable)
- Tender/contract pricing and substitution effects
- Availability and supply continuity
What is the upside case?
- Not available from the provided inputs.
What is the downside case?
- Not available from the provided inputs.
Key Takeaways
- A complete, accurate clinical trials update for cefotetan cannot be generated without a validated, current trial dataset.
- A quantified market analysis and projection cannot be produced without current sales baselines, regulatory status confirmation, and validated competitor positioning.
- Patent/exclusivity and generic entry risk cannot be evaluated without Orange Book and patent listing inputs.
FAQs
- Is cefotetan still prescribed for surgical prophylaxis in the US and EU?
- Are there any new cefotetan clinical trials recruiting patients now?
- What alternatives do hospitals substitute for cefotetan in intra-abdominal infections?
- Does cefotetan have any current regulatory actions affecting supply or labeling?
- Can cefotetan be substituted with another cephalosporin for formulary decisions?
References
- No sources cited because no validated dataset (trial registry, FDA Orange Book listing, patent register, or sales figures) was provided in the prompt.
